Greetings,

We have noticed an increase use of monoclonal antibodies (MABs)for non-chemo indications, and when prescribed it has been noticed paperwork or labs are missed.

To safely order MABs for non-chemo indications, how do others utilize the capabilities of their CPOE system? Has this been a concern at any other sites?

Thank you in advance for the responses. It is highly appreciated.

Jessa

Hello!

Our institution has started a discussion around what PPE and preparation precautions should be in place for monoclonal antibodies (in both the inpatient and ambulatory setting). We recognize that the only monoclonal antibodies that fall on the NIOSH hazardous drug list include those that are conjugated to an antineoplastic (eg, gemtuzumab)... whereas other commonly used mAbs (eg, infliximab, omalizumab-outpatient) are not present in the list. (I did attach two articles that leaned towards treating these agents as hazardous medications.)